Figure 2. Kaplan-Meier analysis of 5-year relapse-free survival (RFS) and disease-specific survival (DSS) for B-cell lymphoma 2 (BCL2) positive and BCL2-negative patients. Patients expressing BCL2 have longer 5-year RFS (A) (p=0.008) and 5-year DSS (B) (p=0.036) compared to patients with no BCL2 expression.